Durable cell and gene therapies are poised for rapid growth – potentially providing transformative benefits for patients and exacerbating financial challenges for payers, providers, patients, and therapeutic developers. With five … Read More
Dynamic Dossier in the Cloud: A Sociotechnical Architecture for a Real-Time and Metrics-Based Data Tracking System with Gene and Cell Therapies as a Case Study
Published on October 28th in Therapeutic Innovation & Regulatory Science, the article addresses inefficiencies in the system and process of data sharing among stakeholders in the development, access, and use … Read More
FoCUS Monthly Recap: August 2020
UPDATED RESOURCES New pipeline projections, updated stakeholder perspectives in the Paying for Cures Toolkit We’re keeping the Toolkit up to date with our latest analysis of the cell and gene therapy … Read More
Paying for Cures August 2020 virtual conference recap
FoCUS hosted a virtual Paying for Cures one-day conference on August 18 examining the challenges public and private payers face when considering new cell and gene therapies. The latest in … Read More
FoCUS Monthly Recap: July 2020
RESEARCH BRIEF Pipeline analysis: 10x growth, but serious questions Updated projection of US durable cell and gene therapies product-indication approvals based on December 2019 development pipeline. Ongoing pipeline modeling by … Read More
Updated projection of US durable cell and gene therapies product-indication approvals based on December 2019 development pipeline
Ongoing pipeline modeling by the MIT NEWDIGS FoCUS team projects 10X growth from July 2020 levels, but with large uncertainties. Download FoCUS Research Brief 2020F207v51Share the research
NEWDIGS offers comment on CMS Proposed Rule supporting Value-Based Purchasing
On behalf of the NEWDIGS initiative / FoCUS Project, project team members submitted comments on the recent CMS Proposed Rule supporting Value-Based Purchasing (VBP) (CMS-2482-P). With active input from an engaged … Read More
Tracking the CAR-T revolution: Analysis of clinical trials of CAR-T and TCR therapies for the treatment of cancer
Chimeric antigen receptor and T-cell receptor (CAR-T/TCR) cellular immunotherapies have shown remarkable success in the treatment of some refractory B-cell malignancies, with potential to provide durable clinical response for other … Read More
FoCUS Monthly Recap: June 2020
WHITE PAPER Tracking the CAR-T revolution: Analysis of clinical trials of CAR-T and TCR therapies for the treatment of cancerWe look at all available FDA CAR-T/TCR clinical trials for the … Read More
Adaptive Reimbursement: Innovating for Patient Access and Better Outcomes for All
Design Lab panel recap June 10–11, Adaptive Reimbursement was explored at the NEWDIGS LEAPS Design Lab by a panel representing a national provider system, commercial payers, a global biopharmaceutical company, … Read More